Regulation
FDA panel endorses GRAIL’s multi-cancer early detection test
An FDA advisory panel voted 7-2 to endorse GRAIL's Galleri multi-cancer early detection test, finding that its clinical benefits outweigh risks. The panel's recommendation supports the company's pathway toward potential regulatory clearance for this blood-based screening assay designed to detect multiple cancer types in asymptomatic individuals.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network